Главная страница
Навигация по странице:

  • Ortíz-Domínguez A., Berlanga C., Gutiérrez-Mora D.

  • Baranowski W.J.

  • Blanc F., D’Enfert J., Fiessinger S.

  • Southern K.W., Barker P.M., Solis-Moya A.

  • Pierce M., Crampton S., Henry D.

  • Christopher K., Hyatt P.A., Horkan C.

  • Tarantino G., Conca P., Basile V.

  • Fox J.C., Szyjkowski R.S., Sanderson S.O.

  • Chang C.Y., Schiano T.D.

  • Lockwood A.M., Cole S., Rabinovich M.

  • Pérez Moreno J.M., Saldaña González F.J., Puertas Montenegro M., Báez Perea J.

  • Sée A., Weiffenbach E., Bouvry M.

    		•

    антибиотики. Ив. Андреева2, О. У. Стецюк


    Скачать 0.53 Mb.
    НазваниеИв. Андреева2, О. У. Стецюк
    Анкорантибиотики
    Дата26.02.2022
    Размер0.53 Mb.
    Формат файлаpdf
    Имя файлаbezopasnost-makrolidnyh-antibiotikov-kriticheskiy-analiz (1).pdf
    ТипДиплом
    #374255
    страница3 из 3
    1   2   3
    Abouesh A., Stone C., Hobbs W.R. Antimicrobial-induced mania
    (antibiomania): a review of spontaneous reports. J. Clin. Psychophar- macol. 2002; 22 (1): 71—81.
    75. Neff N.E., Kuo G. Acute manic psychosis induced by triple therapy for H. pylori. J Am Board Fam Pract. 2002; 15(1): 66—68.
    76. No authors listed. M ania induced by antimicrobial agents: mainly isoniazid, clarithromycin. Prescrire Int. 2003; 12(67): 183.
    77. Ortíz-Domínguez A., Berlanga C., Gutiérrez-Mora D. A case of clarithromycin-induced manic episode (antibiomania). Int. J. Neuro- psychopharmacol. 2004; 7(1): 99—100.
    78. Brooks J.O. 3rd, Hoblyn J.C. Secondary mania in older adults. Am.
    J. Psychiatry 2005; 162(11): 2033—2038.
    79. Fidan T., Fidan V. Clarithromycin-induced mania in a child. Int. J.
    Clin. Pharmacol. Ther. 2009; 47(6): 402—404.
    80. Baranowski W.J. Clarithromycin-induced hypomania in a child — a case report. Acta Psychiatr. Scand. 2010; 122(3): 267—268.
    81. Treadway G., Pontani D., Reisman A. The safety of azithro- mycin in the treatment of adults with community-acquired respi- ratory tract infections. Int J. Antimicrob. Agents. 2002; 19(3):
    189—194.
    82. Blanc F., D’Enfert J., Fiessinger S. et al. An evaluation of toler- ance of roxithromycin in adults. J. Antimicrob. Chemother. 1987; 20
    (Suppl. B): 179—183.
    83. Oldfi eld E.C. III, Fessel W.J., Dunne M.W., et al. Once weekly azithromycin therapy for prevention of Mycobacterium avium com- plex infection in patients with AIDS: a randomized, double blind, placebo-controlled multicenter trial. Clin. Infect. Dis. 1998; 26:
    611—619.
    84. Southern K.W., Barker P.M., Solis-Moya A. et al. Macrolide an- tibiotics for cystic fi brosis. Cochrane Database Syst. Rev. 2011; 12:
    CD002203.
    85. Pomares X., Montón C., Espasa M. et al. Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations.
    Int J Chron Obstruct. Pulm. Dis. 2011; 6: 449-456.
    86. Mertl S.L. The role of clarithromycin in the prophylaxis of dissemi- nated Mycobacterium avium-intracellulare infection in patients with
    AIDS. Pharmacotherapy 1996; 16: 393—400.
    87. Pierce M., Crampton S., Henry D. et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium
    avium complex infection in patients with advanced acquired immu- nodefi ciency syndrome. N. Engl. J. Med. 1996; 335: 384—391.
    88. Ridgway G.L. Azithromycin in the management of Chlamydia tra-
    chomatis infections. Int. J. STD AIDS 1996; 7(Suppl. 1): 5—8.
    89. Wallace R.J. Jr, Brown B.A., Griffi th D.E. Drug intolerance to high-dose clarithromycin among elderly patients. Diagn. Microbiol.
    Infect Dis. 1993; 16: 215—221.
    53. Christopher K., Hyatt P.A., Horkan C. et al. Clarithromycin use preceding fulminant hepatic failure. Am. J. Gastroenterol. 2002; 97:
    489—490.
    54. de Abajo F.J., Montero D., Madurga M. et al. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br. J. Clin. Pharmacol. 2004; 58: 71—80.
    55. Tarantino G., Conca P., Basile V. et al. A prospective study of acute drug-induced liver injury in patients suffering from nonalcoholic fatty liver disease. Hepatol. Res.2007; 37: 410—415.
    56. Masiá M., Gutiérrez F., Jimeno A. et al. Fulminant hepatitis and fatal toxic epidermal necrolysis (Lyell disease) coincident with clar- ithromycin administration in an alcoholic patient receiving disulfi - ram therapy. Arch Intern Med. 2002; 162(4): 474—476.
    57. Fox J.C., Szyjkowski R.S., Sanderson S.O., et al. Progressive cholestatic liver disease associated with clarithromycin treatment. J.
    Clin. Pharmacol. 2002; 42(6): 676—680.
    58. Bartholow M. Top 200 prescription drugs of 2009. Pharmacy times.
    May 11, 2010.
    59. Белоусов Ю.Б. Лекарственные поражения печени, ассоциируемые с макролидами. Очевидна ли связь Рус. мед. журн, 2011;
    19 (18): 3—7.
    60. Chang C.Y., Schiano T.D. Review article: drug hepatotoxicity. Ali- ment. Pharmacol. Ther. 2007; 25(10): 1135—1151.
    61. Longo G., Valenti C., Gandini G. et al. Azithromycin-induced in- trahepatic cholestasis. Am. J. Med.1997; 102: 217—218.
    62. Macaigne G., Mokbel M., Marty O. et al. Acute pseudoangiocho- litic hepatitis probably induced by azithromycin. Gastroenterol. Clin.
    Biol. 2000; 24: 969—970.
    63. Suriawinata A., Min A.D. A 33-year-old woman with jaundice after azithromycin use. Semin Liver Dis. 2002; 22(2): 207—210 64. Lockwood A.M., Cole S., Rabinovich M. Azithromycin-induced liver injury. Am. J. Hlth Syst. Pharm.2010; 67: 810—814.
    65. Principi N., Esposito S. Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients. Drug Saf.
    1999; 20: 25—41.
    66. FDA, July, 8, 2000. PID# D000539. Drug: Azithromycin. Reac- tion: Hepatic necrosis/hepatic failure. http://www.docstoc.com/
    docs/76282324/Date-January-To-Lisa-Mathis-MD-Associate-
    Director.
    67. Pérez Moreno J.M., Saldaña González F.J., Puertas Montenegro
    M., Báez Perea J. Cholestatic hepatitis caused by midecamycin.
    Gastroenterol Hepatol. 1996; 19(9): 459—461.
    68. Thevenot T., Mathurin P., Martinez F. et al. Acute hepatitis during hypersensitivity syndrome due to midecamycin. Eur J Gastroenterol
    Hepatol. 1997; 9(12): 1249—1250.
    69. Sée A., Weiffenbach E., Bouvry M. Cholestasis during josamycin treatment. Rev. Med. Interne 1986; 7(3): 309—310.
    70. Lavín I., Mundi J.L., Trillo C. et al. Cholestatic hepatitis by josa- mycin. Gastroenterol. Hepatol. 1999; 22(3): 160.
    71. Ponge A., Van Wassenhowe L., Ponge T. et al. Hepatitis during treatment with josamycin. Rev. Med. Interne 1987; 8(1): 117.
    1   2   3

    написать администратору сайта